Overview

Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II/III multicenter study comprising of the double-blind, followed by open-label phases to evaluate and compare the efficacy and tolerability of eltrombopag (SB-497115-GR) in chronic ITP patients
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline